---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016260"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T01:52:48.242035+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences stockholders elect three directors, ratify auditor, approve say-on-pay at 2024 annual meeting

## Summary
- Quorum of ~62% (26,979,468 shares) represented at May 9, 2024 annual meeting.
- Three director nominees elected: Barbier (10.8M for), Robertson (8.9M for), Scannon (10.9M for).
- Ratification of Ernst & Young as auditor approved (26.5M for, 0.4M against).
- Advisory vote on 2023 executive compensation approved (9.4M for, 1.3M against).

## SEC filing metadata
- accession: 0001437749-24-016260
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/0001437749-24-016260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/sava20240513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016260
- JSON: https://secwatch.observer/filing/0001437749-24-016260.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016260.txt

## Key facts
- Shareholder Votes
  FILANA THERAPEUTICS, INC. shareholders approved Advisory vote on 2023 executive compensation at the 2024-05-09 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2024-05-09
  source text: The 2023 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 9,403,571 1,338,907 526,173 15,710,817
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/0001437749-24-016260-index.htm
- Shareholder Votes
  FILANA THERAPEUTICS, INC. shareholders approved Election of three nominees to the Board of Directors at the 2024-05-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-05-09
  source text: Three (3) nominees for election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Remi Barbier 10,768,599 500,052 15,710,817 Sanford R. Robertson 8,944,665 2,323,986 15,710,817 Patrick J. Scannon, M.D., Ph.D. 10,891,367 377,284 15,710,817
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/0001437749-24-016260-index.htm
- Shareholder Votes
  FILANA THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-05-09
  source text: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024, was ratified based upon the following votes: For Against Abstain 26,461,553 380,036 137,879
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000143774924016260/0001437749-24-016260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.